<a id="bm-comp-c3ffae86-d31f-4887-8843-11cacb88a9b9" name="bm-comp-c3ffae86-d31f-4887-8843-11cacb88a9b9" class="BMCustomAnchor"></a><table><tr><td bm-component-id="c3ffae86-d31f-4887-8843-11cacb88a9b9" style="vertical-align: top; width:100.000000%;"><ul><li>-1%/0% adj. EBITDA vs ABGSCe/Infront cons in Q2</li><li>Cons estimates likely unchanged</li><li>Trading at 10.2x '26e EV/EBITDA</li></ul></td></tr></table><a id="bm-comp-725ab908-af1b-49b3-9664-d03d84edc004" name="bm-comp-725ab908-af1b-49b3-9664-d03d84edc004" class="BMCustomAnchor"></a><table><tr><td bm-component-id="725ab908-af1b-49b3-9664-d03d84edc004" style="vertical-align: top; width:100.000000%;"><h3 class="bm-h3">Q2 results: In line with expectations</h3><p>Medicover reported a second quarter in line with cons. Q2 sales were EUR 640m (0% vs ABGSCe, 0% vs cons). Total organic sales growth in the quarter was +12% (ABGSCe +10%). Adj. EBITDA was 109m (-1% vs. ABGSCe, 0% vs. cons), for a margin of 17.1% (ABGSCe 17.3%, cons 17.1%), up 20bps y-o-y. Total NRI in Q2 was EUR -2m (ABGSCe EUR -4m, cons EUR -4m). Healthcare Services had a slightly softer quarter, with organic growth decelerating to 12.2% from 15.6% a year earlier and the EBITDA margin slipping to 18.4% from 18.6%, as continued strength in India, which grew 23.1% (~40% LCCY), and Polish sports/wellness was offset by weaker hospitals in Poland and clinics in Romania. Diagnostic Services performed better, with organic growth of 10.9% and the EBITDA margin improving to 18.8% from 17.7%, supported by double digit FFS growth across key markets and a favourable shift toward more advanced testing. Overall, a solid report with strong organic growth, though margin expansion was smaller than in Q1 as HS offset gains in DS.</p><h3 class="bm-h3" style="text-align:left;">Outlook: Softer in Romania</h3><p style="text-align:left;">Management reiterated the 2026-2028 targets (revenue >EUR 3.25bn, adj. organic EBITDA >EUR 600m, leverage ≤3.0x) and says it is "in line with plan" six months in. Leverage was 2.9x, flat vs Q1 and down from 3.1x at FY25, inside targets. India remains the growth engine (~40% in LCCY), with the two newest hospitals ramping and new specialised centres plus a 100-bed women's/children's hospital added. A negative is Romania. Medicover highlights post-coalition-collapse political instability, 10.7% inflation and a weaker labour market that are pressuring membership and FFS. Otherwise the outlook commentary is strategic; there is no new numerical H2 guidance.</p><h3 class="bm-h3">Conclusion: trading at 10.2x EV/EBITDA '26e</h3><p>Based on the Q2 deviation, we find little reason for cons. to move estimates at all. The stock has been up ~8% L3M and is trading at 10.2x-8.7x EV/EBITDA for '26e-'27e. Conference call at 09.30 CEST today. Link for audiocast <a data-bm-trackable="false" href="https://medicover.events.inderes.com/q2-report-2026/register" target="_blank">here</a>.</p><br /><table id="bm-img-897b1ce4-283d-4ff0-8dc2-9458fdeeb22e" class="bm-img-table xslt-img-empty xslt-img-include"><tr><td class="xslt-img-caption">Deviation table</td></tr><tr><td><img bm-img-encrypt="897b1ce4-283d-4ff0-8dc2-9458fdeeb22e" bm-img-original-height="714" bm-img-original-width="909" bm-img-svg="image:image_upload/97783_8a4974b5-7ca2-471b-8fcd-da7f1b797a25.svg" bm-img-width-hint="100%" id="bm-id-897b1ce4-283d-4ff0-8dc2-9458fdeeb22e" src="https://abgsc.bluematrix.com/images/image_upload/97783_8a4974b5-7ca2-471b-8fcd-da7f1b797a25_733.png" svg="/nas/web/clients/abgsc/images/image_upload/97783_8a4974b5-7ca2-471b-8fcd-da7f1b797a25.svg" width="726" alt="" title="" /></td></tr><tr><td class="xslt-img-source">Source: ABG Sundal Collier, Company data, Infront consensus</td></tr></table></td></tr></table>